Introduction: Tocilizumab (TCZ), a humanized monoclonal antibody directed against interleukin-6 (IL-6) receptors, has been tried in various
studies as a Covid-19 therapy with controversial results.
Aim: To evaluate the effectiveness of adding TCZ to standard care (SC) in critical Covid-19 patients.
Methods: it was designed retrospectively as a comparative study on two paired series of critical patients affected with Covid-19: the 1st group
received TCZ plus SC versus a 2nd group which received only SC. The matching criteria were age, sex and severity score and the matching
was based on the propensity score matching (PSM) by the nearest neighbor. Outcomes were: survival, mechanical ventilation (MV) and
nosocomial infections.
Results: Ninety patients were included by pairing estimated successful (PSM > 0.5 in more than 50% in each group for all matching criteria).
55.5% of SC group progressed to stage 3-acute respiratory distress syndrome (ARDS) versus 31% of TCZ+SC patients (p=0.03). No effect
of TCZ was found on mortality (49% in each group, p=1) nor on MV use (p=0.67). ICU stay was more prolonged in TCZ+SC group (16 versus
8 days, p <10-3). The administration of TCZ induced a significant decrease in CRP but not changed the IL-6 dosage. Nosocomial infections
occurred in 18 (40%) of TCZ+SC group comparatively to 15 (33,5%) of SC group, p=0.66.
Conclusion: Tocilizumab reduced the risk of progression to severe ARDS probably due to its immune-modulating properties. But no beneficial
effect was found on survival or on the use of ventilation.
- The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. JAMA. 2021;326(6):499–518. doi:10.1001/jama.2021.11330
- Acute Respiratory Distress Syndrome: The Berlin Definition. JAMA. 012;307(23):2526-2533. doi:10.1001/jama.2012.5669
- The REMAP-CAP Investigators, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021; 384(16): 1491-502. doi: https://doi. org/10.1101/2021.01.07.21249390
- Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al., COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020. 395(10229): p. 1033-4. https://doi.org/10.1016/S0140-6736(20)30628-0
- RECOVERY Collaborative Group.Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021; 397(10285): 1637-45.
- Hofmaenner DA, Wendel Garcia PD, Ganter CC, Brugger SD, Buehler PK, David S, et al. What every intensivist should know about Tocilizumab. Crit Care 2021;25:262. https://doi. org/10.1186/s13054-021-03696-1
- Keske Ş, Tekin S, Sait B, İrkören P, Kapmaz M, Çimen C, et al. Appropriate use of tocilizumab in COVID-19 infection. Int J Infect Dis 2020; 99:338–43. doi: 10.1016/j.ijid.2020.07.036.
- Zhao J, Cui W, Tian B. Efficacy of tocilizumab treatment in severely ill COVID-19 patients. Crit Care 2020; 24:524.
- Malgie J, Schoones J, Pijls B. Decreased mortality in COVID-19 patients treated with Tocilizumab: A rapid systematic review and meta-analysis of observational studies. Clin Infect Dis 2020;72(11):e742-e749. doi: 10.1093/cid/ciaa1445.
- Lan SH, Lai CC, Huang HT, Chang SP, Lu LC, Hsueh PR. Tocilizumab for severe COVID-19: A systematic review and meta-analysis. Int J Antimicrob Agents 2020;56: 106103.
- Antwi-Amoabeng D, Kanji Z, Ford B, Beutler BD, Riddle MS, Siddiqui F. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review. J Med Virol 2020;92(11), 2516–22. https://doi.org/10.1002/jmv.26038
